Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 May 15;101(10):2290–2296. doi: 10.1172/JCI488

Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.

P Yotnda 1, H Firat 1, F Garcia-Pons 1, Z Garcia 1, G Gourru 1, J P Vernant 1, F A Lemonnier 1, V Leblond 1, P Langlade-Demoyen 1
PMCID: PMC508817  PMID: 9593785

Abstract

Human chronic myelogenous leukemia (CML) is characterized by a translocation between chromosomes 9 and 22 that results in a BCR-ABL fusion gene coding for chimeric proteins. The junctional region of the BCR-ABLb3a2 molecule represents a potential leukemia-specific antigen which could be recognized by cytotoxic T lymphocytes (CTL). In fact, we identified a junctional nonapeptide (SSKALQRPV) which binds to HLA-A2.1 molecules. This peptide, as well as those binding to HLA-A3, -A11, and -B8 molecules (previously identified by others), elicits primary CTL responses in vitro from PBLs of both healthy donors and CML patients. Such CTL recognize HLA-matched, BCR-ABL-positive leukemic cells, implying efficient natural processing and presentation of these junctional peptides. Specific CTL were found at high frequency in 5 of 21 CML patients, suggesting that these epitopes are, to some extent, immunogenic in vivo during the course of the disease. These peptides could be useful for the development of specific immunotherapy in CML patients.

Full Text

The Full Text of this article is available as a PDF (215.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Neriah Y., Daley G. Q., Mes-Masson A. M., Witte O. N., Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986 Jul 11;233(4760):212–214. doi: 10.1126/science.3460176. [DOI] [PubMed] [Google Scholar]
  2. Bocchia M., Korontsvit T., Xu Q., Mackinnon S., Yang S. Y., Sette A., Scheinberg D. A. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996 May 1;87(9):3587–3592. [PubMed] [Google Scholar]
  3. Bocchia M., Wentworth P. A., Southwood S., Sidney J., McGraw K., Scheinberg D. A., Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995 May 15;85(10):2680–2684. [PubMed] [Google Scholar]
  4. Celis E., Tsai V., Crimi C., DeMars R., Wentworth P. A., Chesnut R. W., Grey H. M., Sette A., Serra H. M. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2105–2109. doi: 10.1073/pnas.91.6.2105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cheever M. A., Thompson D. B., Klarnet J. P., Greenberg P. D. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med. 1986 May 1;163(5):1100–1112. doi: 10.1084/jem.163.5.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Chen W., Peace D. J., Rovira D. K., You S. G., Cheever M. A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1468–1472. doi: 10.1073/pnas.89.4.1468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Christinck E. R., Luscher M. A., Barber B. H., Williams D. B. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature. 1991 Jul 4;352(6330):67–70. doi: 10.1038/352067a0. [DOI] [PubMed] [Google Scholar]
  8. Cibotti R., Cabaniols J. P., Pannetier C., Delarbre C., Vergnon I., Kanellopoulos J. M., Kourilsky P. Public and private V beta T cell receptor repertoires against hen egg white lysozyme (HEL) in nontransgenic versus HEL transgenic mice. J Exp Med. 1994 Sep 1;180(3):861–872. doi: 10.1084/jem.180.3.861. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cibotti R., Kanellopoulos J. M., Cabaniols J. P., Halle-Panenko O., Kosmatopoulos K., Sercarz E., Kourilsky P. Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):416–420. doi: 10.1073/pnas.89.1.416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Cullis J. O., Barrett A. J., Goldman J. M., Lechler R. I. Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines. Leukemia. 1994 Jan;8(1):165–170. [PubMed] [Google Scholar]
  11. Fialkow P. J., Jacobson R. J., Papayannopoulou T. Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med. 1977 Jul;63(1):125–130. doi: 10.1016/0002-9343(77)90124-3. [DOI] [PubMed] [Google Scholar]
  12. Gale R. P., Canaani E. An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5648–5652. doi: 10.1073/pnas.81.18.5648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Greenberg P. D., Cheever M. A., Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med. 1981 Sep 1;154(3):952–963. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985 May 1;161(5):1122–1134. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Harding C. V., Unanue E. R. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature. 1990 Aug 9;346(6284):574–576. doi: 10.1038/346574a0. [DOI] [PubMed] [Google Scholar]
  16. Heath W. R., Kjer-Nielsen L., Hoffmann M. W. Avidity for antigen can influence the helper dependence of CD8+ T lymphocytes. J Immunol. 1993 Dec 1;151(11):5993–6001. [PubMed] [Google Scholar]
  17. Konopka J. B., Watanabe S. M., Witte O. N. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984 Jul;37(3):1035–1042. doi: 10.1016/0092-8674(84)90438-0. [DOI] [PubMed] [Google Scholar]
  18. Kurzrock R., Kloetzer W. S., Talpaz M., Blick M., Walters R., Arlinghaus R. B., Gutterman J. U. Identification of molecular variants of p210bcr-abl in chronic myelogenous leukemia. Blood. 1987 Jul;70(1):233–236. [PubMed] [Google Scholar]
  19. Langlade-Demoyen P., Levraud J. P., Kourilsky P., Abastado J. P. Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells. Int Immunol. 1994 Nov;6(11):1759–1766. doi: 10.1093/intimm/6.11.1759. [DOI] [PubMed] [Google Scholar]
  20. Leclerc J. C., Cantor H. T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo. J Immunol. 1980 Feb;124(2):851–854. [PubMed] [Google Scholar]
  21. Lisker R., Casas L., Mutchinick O., Pérez-Chávez F., Labardini J. Late-appearing Philadelphia chromosome in two patients with chronic myelogenous leukemia. Blood. 1980 Nov;56(5):812–814. [PubMed] [Google Scholar]
  22. Ljunggren H. G., Stam N. J., Ohlén C., Neefjes J. J., Höglund P., Heemels M. T., Bastin J., Schumacher T. N., Townsend A., Kärre K. Empty MHC class I molecules come out in the cold. Nature. 1990 Aug 2;346(6283):476–480. doi: 10.1038/346476a0. [DOI] [PubMed] [Google Scholar]
  23. Plata F., Langlade-Demoyen P., Abastado J. P., Berbar T., Kourilsky P. Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo. Cell. 1987 Jan 30;48(2):231–240. doi: 10.1016/0092-8674(87)90426-0. [DOI] [PubMed] [Google Scholar]
  24. Rammensee H. G., Friede T., Stevanoviíc S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41(4):178–228. doi: 10.1007/BF00172063. [DOI] [PubMed] [Google Scholar]
  25. Schwartz R. H. Acquisition of immunologic self-tolerance. Cell. 1989 Jun 30;57(7):1073–1081. doi: 10.1016/0092-8674(89)90044-5. [DOI] [PubMed] [Google Scholar]
  26. Shtivelman E., Lifshitz B., Gale R. P., Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985 Jun 13;315(6020):550–554. doi: 10.1038/315550a0. [DOI] [PubMed] [Google Scholar]
  27. Stam K., Heisterkamp N., Reynolds F. H., Jr, Groffen J. Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity. Mol Cell Biol. 1987 May;7(5):1955–1960. doi: 10.1128/mcb.7.5.1955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Szczylik C., Skorski T., Nicolaides N. C., Manzella L., Malaguarnera L., Venturelli D., Gewirtz A. M., Calabretta B. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 1991 Aug 2;253(5019):562–565. doi: 10.1126/science.1857987. [DOI] [PubMed] [Google Scholar]
  29. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol. 1981 Apr;126(4):1614–1619. [PubMed] [Google Scholar]
  30. Townsend A., Bodmer H. Antigen recognition by class I-restricted T lymphocytes. Annu Rev Immunol. 1989;7:601–624. doi: 10.1146/annurev.iy.07.040189.003125. [DOI] [PubMed] [Google Scholar]
  31. Webb S., Morris C., Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell. 1990 Dec 21;63(6):1249–1256. doi: 10.1016/0092-8674(90)90420-j. [DOI] [PubMed] [Google Scholar]
  32. ten Bosch G. J., Toornvliet A. C., Friede T., Melief C. J., Leeksma O. C. Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells. Leukemia. 1995 Aug;9(8):1344–1348. [PubMed] [Google Scholar]
  33. van Denderen J., Hermans A., Meeuwsen T., Troelstra C., Zegers N., Boersma W., Grosveld G., van Ewijk W. Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia. J Exp Med. 1989 Jan 1;169(1):87–98. doi: 10.1084/jem.169.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES